Sponsors (8)
The bill promotes coordinated federal review and research that could improve lung cancer detection and outcomes for women and other underserved groups, but those benefits depend on funding, a two‑year review delay, and Congressional follow‑through to implement recommendations.
Women at higher risk and patients without classic risk factors (including USPSTF‑recommended groups) could see improved screening, earlier detection, and better outcomes from targeted research and updated strategies.
Coordinated, interagency federal research (HHS, DoD, VA) and multidisciplinary focus may accelerate development of biomarkers, technologies, and environmental/genomic studies that improve diagnosis and treatment.
A required report to Congress within two years increases transparency and sets a clear timeline for recommended program changes and oversight.
Taxpayers could face increased federal spending or redirected resources if the review recommends program changes that require new funding.
The two‑year timeline delays implementation of possible screening and research improvements, slowing benefits to patients (including women) who might gain from earlier action.
If the review identifies statutory barriers but Congress fails to act, recommended improvements could remain unrealized, limiting the bill's practical impact.
Based on analysis of 2 sections of legislative text.
Directs HHS (with DoD and VA) to review and update federal lung cancer research, prevention, screening, diagnosis, and treatment programs to address gaps for women and low‑risk groups and report findings within two years.
Introduced March 26, 2025 by Tina Smith · Last progress June 9, 2026
Requires the Department of Health and Human Services, working with the Departments of Defense and Veterans Affairs, to review and—if needed—update federal lung cancer research, prevention, screening, diagnosis, and treatment programs to better address gaps affecting women and people with few known risk factors. The agencies must evaluate current federally funded research and public health activities, identify research and program opportunities (including environmental, genomic, screening, and biomarker work), assess awareness and public health strategies, and report findings, actions, and remaining barriers to key congressional committees within two years of enactment.